Headquarters: Stockholm, Sweden
Founded: 2015
Status: Public company (Nasdaq Stockholm: ALZCUR)
CEO: Eva-Lotta Allen
Market Cap: ~$100M USD (2026)
Website: alzecure.com
AlzeCure Pharma AB is a Swedish biotechnology company focused on developing novel therapeutics for Alzheimer's disease and other neurodegenerative disorders. The company was founded in 2015 as a spinout from the Karolinska Institutet in Stockholm, Sweden, with the mission of translating academic research on neurotrophic mechanisms into clinical-stage treatments for cognitive disorders.
The company's approach focuses on targeting neurotransmitter systems, particularly the cholinergic system, which is critically involved in memory and cognitive function. Unlike the many companies pursuing amyloid-targeting approaches, AlzeCure takes a distinctly different strategy by enhancing endogenous neuroprotective mechanisms through positive modulation of neurotrophin receptors. This approach aims to protect existing neurons, enhance synaptic function, and preserve cognitive capacity in patients with Alzheimer's disease.
AlzeCure's therapeutic approach is grounded in the cholinergic hypothesis of Alzheimer's disease, which posits that loss of cholinergic neurons in the basal forebrain significantly contributes to cognitive decline:
Historical Context: The cholinergic hypothesis emerged from observations that:
Limitations of Current Approaches: While cholinesterase inhibitors (donepezil, rivastigmine, galantamine) are approved for AD and provide symptomatic benefit, they:
- Do not address the underlying neurodegeneration
- Have limited efficacy and eventually lose effectiveness
- Only replace lost acetylcholine without protecting neurons
AlzeCure's Innovation: Rather than simply increasing acetylcholine levels, AlzeCure aims to protect and enhance the cholinergic system itself through neurotrophin receptor modulation.
The company's lead programs target tropomyosin receptor kinase A (TrkA) and its ligand nerve growth factor (NGF):
TrkA Receptor:
- High-affinity receptor for NGF
- Expressed primarily on cholinergic neurons in the basal forebrain
- Activation promotes neuronal survival, differentiation, and synaptic plasticity
- NGF/TrkA signaling declines with age and in AD
Signaling Pathways:
- PI3K/Akt pathway: Pro-survival signaling, anti-apoptotic
- MAPK/ERK pathway: Neuronal differentiation, synaptic plasticity
- PLCγ pathway: Calcium signaling, neurotransmitter release
Therapeutic Rationale: By positive allosteric modulation of TrkA, AlzeCure's compounds can:
- Enhance cholinergic neuron survival
- Promote synaptic formation and function
- Protect against amyloid and other toxic insults
- Support memory and cognitive processes
AlzeCure maintains a focused pipeline of programs targeting different aspects of AD:
| Program |
Mechanism |
Indication |
Phase |
Status |
| ACD856 |
TrkA positive allosteric modulator |
Alzheimer's Disease |
Phase 1 |
Active |
| ACD680 |
5-HT6 receptor antagonist |
Alzheimer's Disease |
Preclinical |
Research |
| ACD747 |
NGF modulator |
Alzheimer's Disease |
Discovery |
Research |
ACD856 is a first-in-class small molecule that acts as a positive allosteric modulator of the TrkA receptor and its ligand NGF:
TrkA Modulation:
- Binds to an allosteric site on TrkA
- Enhances NGF binding affinity and signaling efficacy
- Does not directly activate TrkA (requires NGF presence)
- Provides physiological activation rather than artificial stimulation
NGF Pathway Activation:
By potentiating NGF signaling, ACD856 promotes:
- Cholinergic neuron survival and function
- Synaptic plasticity and memory formation
- Neuroprotection against various insults
- Enhanced hippocampal cognitive function
Distinct from Amyloid Approaches:
Unlike anti-amyloid antibodies, ACD856:
- Does not target Aβ or tau pathology directly
- Works on downstream effects of neurodegeneration
- May benefit patients regardless of amyloid burden
- Has a different mechanism for cognitive enhancement
ACD856 entered Phase 1 clinical trials in 2024 with a first-in-human study evaluating safety, tolerability, and pharmacokinetics in healthy volunteers:
Phase 1 Program Design:
| Component |
Description |
Status |
| Single ascending dose (SAD) |
Dose-escalation in healthy volunteers |
Completed |
| Multiple ascending dose (MAD) |
Repeat dosing to assess steady-state PK |
Completed |
| Food effect study |
Impact of food on absorption |
Completed |
| Cognitive endpoints |
Exploratory cognitive assessments |
Ongoing |
Study Design Highlights:
- Randomized, double-blind, placebo-controlled
- Single and multiple dose escalation
- PK/PD assessments including neurotrophin levels
- Safety monitoring with cognitive battery
Rationale for Target:
The cholinergic hypothesis of Alzheimer's disease posits that loss of cholinergic neurons contributes significantly to cognitive decline. By enhancing TrkA/NGF signaling, ACD856 aims to:
- Protect cholinergic neurons from degeneration through enhanced pro-survival signaling
- Enhance synaptic plasticity and memory formation through strengthened neuronal connections
- Provide symptomatic benefit through a non-amyloid mechanism
- Potentially modify disease progression by preserving functional neurons
ACD856 has demonstrated significant preclinical activity:
In Vitro Studies:
- TrkA activation in cell-based assays
- Neuroprotection against toxic insults
- Enhanced synaptic markers in neuronal cultures
In Vivo Studies:
- Improved performance in memory tasks (Morris water maze, novel object recognition)
- Increased hippocampal synaptic density
- Enhanced cholinergic neuron survival in AD models
- Good brain penetration and exposure
Translational Biomarkers:
- Target engagement biomarkers in development
- CSF sampling for pharmacodynamic assessments
- Neuroimaging endpoints under consideration
AlzeCure leverages a proprietary platform developed from academic research at Karolinska Institutet:
| Platform |
Application |
Status |
| Neurodegeneration models |
In vitro and in vivo disease modeling |
Established |
| Cognitive testing |
Rodent behavioral assays |
Validated |
| Pharmacokinetics |
PK/PD optimization |
Active |
| Medicinal chemistry |
Lead optimization |
Ongoing |
The company's drug discovery process integrates:
- Target identification from academic research
- High-throughput screening for lead compounds
- Structure-activity relationship optimization
- In vitro pharmacology characterization
- In vivo efficacy testing in disease models
- Clinical candidate selection and advancement
AlzeCure maintains academic collaborations:
- Karolinska Institutet: Ongoing research partnership
- Swedish universities: Basic neuroscience research
- European Union: Research funding collaborations
- Swedish research councils: Grant support
The company has also received funding from:
- European Innovation Council
- Vinnova (Swedish innovation agency)
- Swedish Research Council
The 5-HT6 receptor is a promising target for Alzheimer's disease cognitive enhancement:
5-HT6 Receptor Biology:
- G-protein coupled receptor expressed in brain regions important for cognition
- Modulates GABAergic, glutamatergic, and cholinergic neurotransmission
- Antagonism enhances cognitive function in preclinical models
- Several 5-HT6 antagonists have been in clinical development
Rationale for 5-HT6 Antagonism:
- 5-HT6 antagonists enhance acetylcholine release
- Improve glutamatergic signaling important for learning
- Reduce GABAergic inhibition in hippocampal circuits
- Have shown cognitive benefits in clinical trials
ACD680 is in preclinical development with the goal of advancing to IND-enabling studies:
- Lead optimization completed
- In vivo efficacy demonstrated
- Safety assessment initiated
ACD747 represents a different approach to neurotrophin modulation:
- Modulates NGF directly or its interactions with TrkA
- Novel mechanism distinct from TrkA PAMs
- Currently in discovery phase
- May provide different pharmacodynamic effects
- Could be combined with ACD856 in future
- Addresses additional aspects of neurotrophin biology
AlzeCure is a publicly traded company listed on Nasdaq Stockholm:
| Metric |
Value |
| Stock exchange |
Nasdaq Stockholm |
| Ticker |
ALZCUR |
| Market cap |
~$100M USD |
| Cash position |
Sufficient for operations through 2026 |
Funding History:
- IPO on Nasdaq Stockholm (2019)
- Multiple equity offerings
- Grant funding from EU and Swedish sources
- Ongoing business development efforts
¶ Competitive Landscape
AlzeCure operates in the Alzheimer's disease therapeutic space:
| Company |
Drug/Approach |
Mechanism |
Status |
| AlzeCure |
ACD856 |
TrkA PAM |
Phase 1 |
| Neurocentria |
NC-601 (Magnesium L-threonate) |
NMDA modulation |
Phase 2 |
| Cognition Therapeutics |
CT1812 |
Sigma-2 receptor antagonist |
Phase 2 |
| AstraZeneca |
AZD0530 |
Src inhibition |
Phase 2 |
| Cerevel |
CVL-231 |
M1 PAM |
Phase 2 |
| Company |
Drug |
Target |
Status |
| AlzeCure |
ACD856 |
TrkA |
Phase 1 |
| Axovant |
intepirdine |
5-HT6 antagonist |
Failed Phase 3 |
| Heptares |
HTL0018318 |
M1 PAM |
Phase 2 |
| AstraZeneca |
AZD2327 |
M1 PAM |
Phase 2 |
AlzeCure's differentiation comes from:
- Direct enhancement of neurotrophin signaling
- Non-amyloid mechanism
- Focus on neuroprotection rather than symptomatic relief
- Strong academic foundation from Karolinska
The Alzheimer's disease market represents significant opportunity:
- Global AD therapeutics: $10B+ annually
- Projected 2030: $20B+ with disease-modifying therapies
- Unmet need: Significant for non-amyloid approaches
AlzeCure's approach addresses:
- Limited amyloid efficacy: Many anti-amyloid approaches show modest benefit
- Symptomatic gap: No disease-modifying options currently approved
- Patient heterogeneity: Mechanism may benefit diverse patient populations
- Combination potential: Could be combined with other approaches
- Clear regulatory pathway with established endpoints
- Potential for accelerated approval based on biomarker evidence
- Flexible development options (monotherapy or combination)
¶ Challenges and Risks
- Clinical success uncertainty: Phase 1 results will determine path forward
- Competition: Many companies in AD space, limited success to date
- Regulatory requirements: May require large Phase 3 programs
- Funding needs: Significant capital required for late-stage development
- Partnership dependence: May need pharma partnership for commercialization
- Market access: Pricing and reimbursement challenges in AD
- Competition from biosimilars: Future generic competition
- Complete Phase 1 clinical trials
- Evaluate Phase 2 readiness
- Assess partnership opportunities
- Advance ACD680 toward IND
- Potential Phase 2 initiation for ACD856
- Regulatory interactions for pivotal trial design
- Business development for commercialization partnership
- Continued pipeline advancement
- Establish clinical proof-of-concept for ACD856
- Build evidence for neurotrophin modulation in AD
- Leverage academic network for continued innovation
- Position for potential acquisition or partnership
AlzeCure's programs interface with key Alzheimer's disease mechanisms:
AlzeCure's approach has potential applicability to:
AlzeCure operates within the Swedish biotech ecosystem:
- Karolinska Institutet (founding institution)
- Stockholm University
- Uppsala University
- Pharmaceutical companies (potential partnership)
- Contract research organizations
- Academic medical centers for clinical trials
- European Innovation Council
- Vinnova
- Swedish Research Council